Results 171 to 180 of about 1,543,622 (248)

Impact of clinical pathways on enhancing compliance with evidence-based therapies for Heart failure with reduced ejection fraction-A retrospective cohort study. [PDF]

PLoS One
Kanaparthy NS, Possick S, Teng W, Maulion C, Kim N.   +4 more
europepmc   +1 more source

GRADE-ADOLOPMENT of clinical practice guidelines and creation of clinical pathways for the primary care management of chronic respiratory conditions in Pakistan. [PDF]

BMC Pulm Med, 2023
Martins RS, Hussain H, Chaudry M, Rizvi NA, Mustafa MA, Ayub B, Aamdani SS, Rehman AA, Pervez A, Nadeem S, Khalid R, Ali AS, Shahid S, Zubairi ABS, Haider AH, Irfan M.   +15 more
europepmc   +1 more source

Clinical effect of acupuncture on knee osteoarthritis and its effect on p38 MAPK signaling pathway

Ye Wei
openalex   +1 more source

Supplementary Figure 13 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis [PDF]

Bilal A. Siddiqui, Nicolas L. Palaskas, Sreyashi Basu, Yibo Dai, Zhong He, Shalini S. Yadav, James P. Allison, Rahul A. Sheth, Sudhakar Tummala, L. Maximilian Buja, Meenakshi B. Bhattacharjee, Cezar Iliescu, Anishia Rawther-Karedath, Anita Deswal, Linghua Wang, Padmanee Sharma, Sumit K. Subudhi   +16 more
openalex   +1 more source

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source

Improving Customisation in Clinical Pathways by Using a Modular Perspective. [PDF]

Int J Environ Res Public Health, 2021
van Dam A, Metz M, Meijboom B.
europepmc   +1 more source

Supplementary Figure 2 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis [PDF]

Bilal A. Siddiqui, Nicolas L. Palaskas, Sreyashi Basu, Yibo Dai, Zhong He, Shalini S. Yadav, James P. Allison, Rahul A. Sheth, Sudhakar Tummala, L. Maximilian Buja, Meenakshi B. Bhattacharjee, Cezar Iliescu, Anishia Rawther-Karedath, Anita Deswal, Linghua Wang, Padmanee Sharma, Sumit K. Subudhi   +16 more
openalex   +1 more source

Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition

Molecular Oncology, EarlyView.
We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li, Shuichi Tatarano, Hirofumi Yoshino, Saeki Saito, Mitsuhiko Tominaga, Junya Arima, Ikumi Fukuda, Takashi Sakaguchi, Ryosuke Matsushita, Yasutoshi Yamada, Hideki Enokida   +10 more
wiley   +1 more source

Enhancing patient safety and risk management through clinical pathways in oncology. [PDF]

BMJ Open Qual
Milanesi M, Fiorito R, Caloccia L, Guglielmetti C, Giganti G, Andreasi SE, Triarico A.   +6 more
europepmc   +1 more source

BPM Support for Patient-Centred Clinical Pathways in Chronic Diseases. [PDF]

Sensors (Basel), 2021
Szelągowski M, Berniak-Woźny J, Lipiński C.   +2 more
europepmc   +1 more source